6.56

2.24% -0.15

Sage Therapeutics Inc (SAGE)

Overview News Price History Option Chain Financials Why SAGE Down? Discussions Forecast

Sage Therapeutics Inc stock is traded at $6.56, with a volume of 997.94K. It is down -2.24% in the last 24 hours and down -5.20% over the past month. Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.

Previous Close:

$6.71

Open:

$6.73

24h Volume:

997.94K

Relative Volume:

0.79

Market Cap:

$457.13M

Revenue:

$91.06M

Net Income/Loss:

$-503.14M

P/E Ratio:

-0.7819

EPS:

-8.39

Net Cash Flow:

$-424.74M

1W Performance:

-10.14%

1M Performance:

-5.20%

6M Performance:

+3.96%

1Y Performance:

-46.84%

1-Day Range:

$6.50

$6.89

1-Week Range:

$6.50

$7.36

52-Week Range:

$4.62

$13.47

Sage Therapeutics Inc Stock (SAGE) Company Profile

Name

Sage Therapeutics Inc

Sector

Healthcare (1153)

Industry

Biotechnology (676)

Phone

617-299-8380

Address

55 CAMBRIDGE PARKWAY, CAMBRIDGE, MA

Employee

487

Twitter

@SageBiotech

Next Earnings Date

2025-02-11

Latest SEC Filings

SAGE's Discussions on Twitter

Compare SAGE with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SAGE Sage Therapeutics Inc	6.56	457.13M	91.06M	-503.14M	-424.74M	-8.39
VRTX Vertex Pharmaceuticals Inc	424.99	128.84B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	527.78	65.38B	14.09B	4.50B	2.96B	39.28
ARGX Argen X Se Adr	549.65	39.67B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	251.15	33.82B	2.35B	-269.70M	-75.39M	-2.09
ONC Beigene Ltd Adr	231.99	27.60B	3.81B	-644.79M	-669.77M	-6.24

Sage Therapeutics Inc Stock (SAGE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-11-25	Resumed	BofA Securities	Underperform
Nov-21-24	Upgrade	RBC Capital Mkts	Underperform → Sector Perform
Oct-10-24	Resumed	Raymond James	Mkt Perform
Oct-04-24	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Jul-30-24	Downgrade	TD Cowen	Buy → Hold
Jul-25-24	Downgrade	JP Morgan	Overweight → Neutral
May-29-24	Initiated	Citigroup	Sell
May-29-24	Initiated	Robert W. Baird	Neutral
Apr-17-24	Downgrade	BofA Securities	Neutral → Underperform
Dec-12-23	Initiated	Deutsche Bank	Hold
Aug-08-23	Downgrade	Canaccord Genuity	Buy → Hold
Aug-08-23	Downgrade	Goldman	Buy → Neutral
Aug-08-23	Downgrade	Needham	Buy → Hold
Aug-07-23	Downgrade	BofA Securities	Buy → Neutral
Aug-07-23	Downgrade	Oppenheimer	Outperform → Perform
Aug-07-23	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Aug-07-23	Downgrade	Stifel	Buy → Hold
Aug-07-23	Downgrade	Wedbush	Outperform → Neutral
Jul-27-23	Initiated	Scotiabank	Sector Outperform
Mar-13-23	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Jan-03-23	Downgrade	Guggenheim	Buy → Neutral
Nov-01-22	Initiated	Loop Capital	Hold
Mar-31-22	Initiated	Berenberg	Hold
Nov-02-21	Upgrade	Guggenheim	Neutral → Buy
Oct-19-21	Resumed	Morgan Stanley	Equal-Weight
Oct-07-21	Downgrade	Jefferies	Buy → Hold
Sep-23-21	Initiated	Needham	Buy
Jun-16-21	Downgrade	Citigroup	Buy → Neutral
Apr-07-21	Initiated	Piper Sandler	Overweight
Feb-26-21	Downgrade	Mizuho	Buy → Neutral
Feb-25-21	Reiterated	H.C. Wainwright	Neutral
Feb-02-21	Resumed	Raymond James	Mkt Perform
Jan-22-21	Downgrade	BMO Capital Markets	Outperform → Market Perform
Jan-04-21	Upgrade	Guggenheim	Neutral → Buy
Jan-04-21	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Dec-04-20	Upgrade	Mizuho	Neutral → Buy
Dec-01-20	Downgrade	Raymond James	Outperform → Mkt Perform
Nov-16-20	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Nov-06-20	Reiterated	H.C. Wainwright	Neutral
Sep-11-20	Upgrade	Wedbush	Neutral → Outperform
Aug-10-20	Upgrade	Raymond James	Mkt Perform → Outperform
May-08-20	Downgrade	Wedbush	Outperform → Neutral
Apr-08-20	Downgrade	Guggenheim	Buy → Neutral
Mar-18-20	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Mar-06-20	Initiated	Citigroup	Buy
Feb-28-20	Reiterated	H.C. Wainwright	Neutral
Feb-06-20	Initiated	Mizuho	Neutral
Dec-06-19	Reiterated	RBC Capital Mkts	Outperform
Dec-05-19	Reiterated	Guggenheim	Buy
Dec-05-19	Downgrade	SunTrust	Buy → Hold
Oct-30-19	Initiated	H.C. Wainwright	Neutral
May-23-19	Initiated	Wedbush	Outperform
Apr-25-19	Initiated	Jefferies	Buy
Dec-14-18	Initiated	Wolfe Research	Outperform
Oct-11-18	Initiated	Oppenheimer	Outperform

View All

Sage Therapeutics Inc Stock (SAGE) Latest News

03:41 AM

Wells Fargo & Company MN Boosts Stock Position in Sage Therapeutics, Inc. (NASDAQ:SAGE) - Defense World

03:41 AM

May 08, 2025

Invesco Ltd. Purchases 4,629 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) - Defense World

May 04, 2025

Q2 Earnings Forecast for Sage Therapeutics Issued By Wedbush - Defense World

May 04, 2025

May 02, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

May 02, 2025

What is HC Wainwright’s Forecast for SAGE Q1 Earnings? - Defense World

May 02, 2025

May 01, 2025

Sage Therapeutics' Q1 Earnings Miss Mark, Revenue Rise Y/Y - MSN

May 01, 2025

Sage Therapeutics, Inc. (NASDAQ:SAGE) Q1 2025 Earnings Call Transcript - Insider Monkey

May 01, 2025

Apr 30, 2025

Sage Therapeutics’ Earnings Call Highlights Growth and Uncertainty - TipRanks

Apr 30, 2025

Balance Sheet Breakdown: Sage Therapeutics Inc (SAGE)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - DWinneX

Apr 30, 2025